Current Issues of Pharmacy and Medical Sciences

Risk of peritoneal dissemination in stomach cancer

Curr Issues Pharm Med Sci., Vol. 30, No. 4, 184-186

Robert Sitarz1,2*, Wojciech P Polkowski3, Ryszard Maciejewski2, G Johan A Offerhaus

1 Department of Pathology, University Medical Center Utrecht, The Netherlands 
2 Department of Anatomy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland
3 Department of Surgical Oncology, Medical University of Lublin, Poland

DOI: https://doi.org/10.1515/cipms-2017-0034

Abstract

With regard to gastric cancer, an important disease and a public health problem, it is expected that understanding the molecular make up of carcinomas will provide us with more precise targets for therapy. Indeed advanced molecular technology has made it possible to classify according to genotype instead of phenotype. For advanced stomach cancer, however, surgery is still the only option for cure. Yet, also after surgery, more than 50% of the patients will die of peritoneal dissemination of their disease. This review looks at the molecular mechanism of peritoneal spread of stomach cancer in order to arrive at a risk profile that enables medical personnel to raise the index of suspicion for peritoneal carcinomatosis. The peritoneal cancer index (PCI) provides a scoring system to measure the extent of peritoneal spread during laparoscopic staging. A recently developed device called the ‘MacSpec pen’ maybe of use to confirm the presence of tumor when there is doubt about the diagnosis. Treatment of peritoneal dissemination consists of cytoreduction, combined with hyperthermic peritoneal chemotherapy (HIPEC).

Full text


Keywords

gastric cancer, peritoneal dissemination, biomarkers, risk profile, immunohistochemistry

Calendar

July 2019

Mon Tue Wed Thu Fri Sat Sun
01 02 03 04 05 06 07
08 09 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31